News

GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences

CARLSBAD, Calif., /PRNewswire/ — GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system‘s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry

Cell therapies, typically made from a patient’s own cells, are increasingly important in the fight against cancer and other critical diseases. Curate Biosciences provides a superior cell separation, wash, and concentration solution to deliver more biologically potent results for revolutionary cell therapy treatments. 

The company’s Curate® Cell Processing System is a robust, simple, and automated system that has the potential to enable up to a 50% reduction in the total cost of autologous cell therapy production and a like reduction in the days required to produce a CAR-T dose. The Curate System more than doubles the recovery of patient-derived white blood cells and CD3+ T cell subsets, with exceptional purity in a single-step, closed microfluidic system. 

“Users are now testing the Curate System via our Technology Access Program and observing firsthand its innovative and industry leading ability to produce more high-quality white blood cells for CAR-T oncology cures,” said Mike Grisham, Curate Bioscience’s Chief Executive Officer. “GPB in our prior company name stood for getting people better,’ and this remains our core mission, but the new name reflects our unique capacity to provide more high-quality cells to produce cures for once-intractable diseases.

For more information visit https://www.curatebio.com/

Recent News

12/05/2022

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs. CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market

12/01/2022

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.